Trial Profile
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Irinotecan (Primary) ; Palbociclib (Primary) ; Palbociclib (Primary) ; Temozolomide (Primary) ; Temozolomide (Primary) ; Topotecan (Primary)
- Indications CNS cancer; Diffuse intrinsic pontine glioma; Ewing's sarcoma; Glioma; Medulloblastoma; Neuroblastoma; Rhabdoid tumour; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 29 Feb 2024 Planned primary completion date changed from 30 Aug 2024 to 24 Aug 2024.
- 29 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2024 Planned primary completion date changed from 29 Feb 2024 to 30 Aug 2024.